TCT23 Late-breakers: Full Schedule Announced
Late-breaking trials will be presented during the main sessions and highlighted during press conferences scheduled for Oct. 24, 25 and 26
Source: dicardiology.com
Page 7 - Clinical Trial Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Clinical Trial Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Clinical Trial Program Today - Breaking & Trending Today
Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
TARRYTOWN, N.Y. and PARIS, Oct. 20, 2023 -- Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for the...
Source: marketscreener.com
Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up t
Clinical response was maintained at 73.2% for Psoriasis Area and Severity Index (PASI) 75 with three years of continuous Sotyktu treatment in the POETYK PSO long-term extension trialSotyktu demonstrated a consistent safety profile with no increases in adverse events or serious adverse events and no emergence of any...
Source: pharmiweb.com
Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration
88% of all aflibercept 8 mg patients were on a ≥12-week dosing interval at the end of two years 78% of all aflibercept 8 mg patients maintained ≥12-week dosing intervals throughout the two-year... -Today at 07:03 am- MarketScreener
Source: marketscreener.com
REGENERON PHARMACEUTICALS, INC. - AFLIBERCEPT 8 MG TWO-YEAR RESULTS FROM PIVOTAL PHOTON TRIAL IN DIABETIC MACULAR EDEMA PRESENTED AT ASRS
TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced the first presentation of positive two-year results from the pivotal PHOTON trial investigating aflibercept 8 mg with 12- and 16-week...
Source: marketscreener.com